Please login to the form below

Not currently logged in
Email:
Password:

US government advisers urge FDA to speed up drug approval process

Calls for greater partnership between public and private sectors

FDA headquarters White Oak

The number of innovative new medicines approved in the US should be doubled within the next 10 to 15 years, according to advisors to the US government.

The President's Council of Advisors on Science and Technology (PCAST) has released a report that calls for the Food and Drug Administration (FDA) to accelerate the rate of drug approvals, while increasing drug safety at the same time.

To do this, two key issues need to be address, said the Propelling Innovation in Drug Discovery, Development, and Evaluation report.

First, researchers need to improve their methodologies and tools in order to more appropriately translate clinical research into research that addresses actual therapeutic needs.

In addition, pharmaceutical companies and regulators, such as the FDA, need to “incorporate new efficiencies” into clinical trials, with the Pharmaceutical Research and Manufacturers of America (PhRMA) reporting that one medicine takes, on average, 10 to 15 years to develop at a cost of about $1.2bn.

To achieve these goals, the PCAST has recommended the creation of a public-private collaboration called Partnership to Accelerate Therapeutics.

This would involve representatives from the pharma industry, as well as academic researchers, healthcare professional organisations, advocacy groups and the US government.

According to the PCAST, such a partnership would identify actions that could be taken to speed up the drug development process, minimise the duplication of efforts and appease all stakeholders.

“With improved collaboration among all the participants in the drug development ecosystem and optimisation of drug-evaluation pathways, American researchers and companies should be able to accelerate the development of safe and effective drugs while also strengthening the US economy,” said Eric Lander, co-chair of the PCAST.

The call comes despite research demonstrating the FDA is leading the way, both in the number of drugs approved and the speed of approval, compared to its counterparts in the EU and Canada.

27th September 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....